SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
GEVA was delisted on the 22nd of June, 2015.
115 hedge funds and large institutions have $2.68B invested in SYNAGEVA BIOPHARMA CORP COM STK (DE) in 2014 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 41 increasing their positions, 28 reducing their positions, and 7 closing their positions.
457% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 7
46% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 28
37% more funds holding
Funds holding: 84 → 115 (+31)
35% more capital invested
Capital invested by funds: $1.98B → $2.68B (+$702M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
64% less call options, than puts
Call options by funds: $13.9M | Put options by funds: $38.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$44.7M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$34.7M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$31.9M |
| 4 |
DM
Deerfield Management
New York
|
+$29.4M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
+$24.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$32.4M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$25.3M |
| 3 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$20.4M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$14.1M |
| 5 |
FAM
Fred Alger Management
New York
|
-$11.5M |
GEVA Hedge Fund Activity: Q1 2014 in Review
115 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) for Q1 2014, worth a combined $2.68B — up 35% from $1.98B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new GEVA positions and 7 closed out — a net gain of 32 holders — while 41 added to existing stakes and 28 trimmed.
The largest buyer was Capital World Investors, adding an estimated $44.7M. The largest seller was Fidelity Investments, cutting an estimated $32.4M.
- 115 institutional investors held SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) as of Q1 2014, up from 84 in Q4 2013.
- Funds reported $2.68B of SYNAGEVA BIOPHARMA CORP COM STK (DE) stock for Q1 2014, up 35% quarter-over-quarter.
- 39 funds opened new SYNAGEVA BIOPHARMA CORP COM STK (DE) positions in Q1 2014 and 7 closed out, a net change of +32 holders.
- The largest SYNAGEVA BIOPHARMA CORP COM STK (DE) buyer in Q1 2014 was Capital World Investors, an estimated $44.7M added.
- The largest SYNAGEVA BIOPHARMA CORP COM STK (DE) seller in Q1 2014 was Fidelity Investments, an estimated $32.4M sold.
Based on aggregated 13F filings for Q1 2014.